Institut de Cancérologie de Lorraine   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Vandœuvre-lès-Nancy France (1924)

Organization Overview

First Clinical Trial
2011
NCT02866955
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Institut de Cancérologie de Lorraine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Endometrial Neoplasms (Phase 3)

Fibrosis (Phase 3)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Rectal Neoplasms (Phase 3)

Recurrence (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Vulvar Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 17